Skin and Soft Tissue Infections
Currently, no means exist to accelerate the availability of bacterial identification and antibiotic susceptibility for S. aureus in skin and soft tissue infections. MicroPhage intends to introduce an MRSA/MSSA Skin and Soft Tissue Infection Test that is designed to rapidly identify the presence of S. aureus and determine methicillin resistance (MRSA) and methicillin susceptibility (MSSA). Additional bacterial pathogen ID/ASTs may also be made available.
Using our easy-to-use bacteriophage amplification platform, the test will provide high quality results in hours without the need for expensive equipment, batching, or specialized personnel. By providing results days before traditional ID/AST results, the MicroPhage test will enable more effective treatment and improved patient care.
This test is not cleared by the U.S. FDA nor CE Marked and not yet available for sale.